Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimen...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 842 0100

Website: www.lisata.com

Address:

110 Allen Road, 2nd Floor, Basking Ridge, United States

BillionerOfKing Feb. 3 at 12:39 PM

$LSTA Current Stock Price: $4.57

0 · Reply

KP2021 Jan. 30 at 7:57 PM

$LSTA shorts have decreased https://www.benzinga.com/insights/short-sellers/26/01/50232004/what-does-the-market-think-about-lisata-therapeutics-inc

0 · Reply

PyraWeb Jan. 28 at 3:53 PM

$LSTA PyraWeb a breakout here STARTS at 9.63, everything else is weak defeat…see how recent candle stopped at sine wave, that tells you this is all still very controlled PA. Needs to disconnect from the algo, only way is clearing cap lvl. I’m praying Mazzo and co have finally found some creativity at the 11th hour to get this moving. We need more news! Is it their intention to sell at $4? Or was the intention to get world rights back and hope for a buyer to pop up? A few bidders maybe? I have no idea what their plan is…but this $4-5 BS isn’t it. 🙏

2 · Reply

KP2021 Jan. 28 at 1:30 PM

$LSTA

0 · Reply

KP2021 Jan. 28 at 1:26 PM

$LSTA KAVA IPO https://insights.citeline.com/scrip/business/deals/deal-watch/deal-watch-kuva-labs-to-go-public-via-merger-with-licensing-partner-lisata-TP6E7MWWG5DN7GRG6KRJTQZXTQ/

0 · Reply

KP2021 Jan. 28 at 1:19 PM

Could be another Warner Bros bid war $LSTA

0 · Reply

sionist Jan. 28 at 12:53 PM

$BCAB Additionally, $LSTA's tender offer leaves gatc with bioatla as its only partner now. What it means? GATC has top tier AI technology with a predictive accuracy of 91 percent, which is certified by UCI. The core theme of JPM2026 is the development of new AI drugs, and many companies are jumping into the market, including Nvidia thermofisher Lily. Megatrend. GATC also has a former chairman of the White House economic advisory committee. Is delisting possible?

1 · Reply

Defen Jan. 27 at 8:49 PM

$LSTA jumped early on this one

0 · Reply

ChazzyTrades Jan. 27 at 6:59 PM

$LSTA Buying here

0 · Reply

TwongStocks Jan. 27 at 3:15 PM

$LSTA This is now an arbitrage play. Per the binding term sheet, Kuva is obligated to pay: • $4 upfront • $1 CVR if the certepetide rights in China revert back to LSTA from Qilu • $1 CVR when Kuva files an NDA for any indication LSTA confirmed today that they terminated the license agreement with Qilu and that the rights in China will revert back to LSTA. So we know that one of the CVRs will pay out. Which puts the BO price at $5. LSTA is still trading ~$4.50. Market hasn't fully digested this yet. Right now the biggest risk is if this deal falls through. They have until Feb 27 to sign a definitive purchase agreement.

1 · Reply

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Jan 21, 2026, 7:00 AM EST - 14 days ago

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Nov 6, 2025, 7:46 PM EST - 3 months ago

Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 3 months ago

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 3 months ago

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

Nov 4, 2025, 4:00 PM EST - 3 months ago

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Oct 13, 2025, 8:00 AM EDT - 4 months ago

Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 8, 2025, 8:30 AM EDT - 4 months ago

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Sep 29, 2025, 8:00 AM EDT - 4 months ago

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Sep 2, 2025, 8:00 AM EDT - 5 months ago

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 8, 2025, 3:05 AM EDT - 6 months ago

Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 7 months ago

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

Jul 15, 2025, 8:00 AM EDT - 7 months ago

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

Jun 17, 2025, 8:00 AM EDT - 8 months ago

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Jun 11, 2025, 8:30 AM EDT - 8 months ago

Lisata Therapeutics to Present at the 2025 BIO International Convention

May 8, 2025, 9:57 PM EDT - 9 months ago

Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript

May 8, 2025, 4:05 PM EDT - 9 months ago

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 9 months ago

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Apr 15, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics Announces Research License with Catalent

Mar 6, 2025, 8:30 AM EST - 11 months ago

Lisata Therapeutics to Present at the Investival Showcase USA

Mar 5, 2025, 8:30 AM EST - 11 months ago

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Feb 27, 2025, 10:06 PM EST - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 1 year ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

Jan 15, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Dec 10, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Nov 19, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Nov 12, 2024, 10:07 PM EST - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 9:23 AM EST - 1 year ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Nov 6, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Aug 13, 2024, 12:20 AM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Jun 13, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

May 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

May 20, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

May 9, 2024, 9:42 PM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Apr 23, 2024, 7:30 AM EDT - 1 year ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

BillionerOfKing Feb. 3 at 12:39 PM

$LSTA Current Stock Price: $4.57

0 · Reply

KP2021 Jan. 30 at 7:57 PM

$LSTA shorts have decreased https://www.benzinga.com/insights/short-sellers/26/01/50232004/what-does-the-market-think-about-lisata-therapeutics-inc

0 · Reply

PyraWeb Jan. 28 at 3:53 PM

2 · Reply

KP2021 Jan. 28 at 1:30 PM

$LSTA

0 · Reply

KP2021 Jan. 28 at 1:26 PM

$LSTA KAVA IPO https://insights.citeline.com/scrip/business/deals/deal-watch/deal-watch-kuva-labs-to-go-public-via-merger-with-licensing-partner-lisata-TP6E7MWWG5DN7GRG6KRJTQZXTQ/

0 · Reply

KP2021 Jan. 28 at 1:19 PM

Could be another Warner Bros bid war $LSTA

0 · Reply

sionist Jan. 28 at 12:53 PM

1 · Reply

Defen Jan. 27 at 8:49 PM

$LSTA jumped early on this one

0 · Reply

ChazzyTrades Jan. 27 at 6:59 PM

$LSTA Buying here

0 · Reply

TwongStocks Jan. 27 at 3:15 PM

1 · Reply

Stmkr Jan. 27 at 3:11 PM

$LSTA Acquisition price $4.X + first CVR $1.X = $5 + potentially 2nd CVR at $1.X Yet stock trading at $4.5 still. Makes sense...

0 · Reply

MakingDreamsReality Jan. 27 at 2:25 PM

PM mOOvers👀 $HIND -Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study $NTLA -Intellia Therapeutics Announces FDA Removes Clinical Hold On Its Investigational New Drug application For MAGNITUDE-2 Phase 3 Clinical Study Of Nexiguran Ziclumeran $RR - Richtech Robotics Collaborates with Microsoft to Advance Agentic AI in Real-World Robotics Applications $FLGC -Flora Growth Corp. Announces Name Change to ZeroStack Corp., Furthering Its Strategy as an AI-Focused Asset Management Company $LSTA -Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

1 · Reply

Stmkr Jan. 27 at 1:25 PM

$LSTA As expected. Wake up mr Market. Acquisition at $4.X + $1.X CVR = $5 Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide Already predicted this would happen: https://substack.com/@biotechpharmainvestor/note/c-203318413?r=2nece1

0 · Reply

TwongStocks Jan. 27 at 1:15 PM

$LSTA Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-mutual-termination-license One of the two CVRs from the Kuva buyout was contingent in the certepetide rights in China being reverted back to LSTA from Qilu. This almost guarantees that this particular CVR will be paid out. So shareholder should see at least $5 from Kuva.

0 · Reply

DARKP00L Jan. 27 at 1:14 PM

$LSTA 08:05 on Jan. 27 2026 Lisata Therapeutics, Qilu Pharmaceutical Mutually Terminate 2021 License And Collaboration Agreement #tradeideas

0 · Reply

Defen Jan. 24 at 1:20 AM

$LSTA I’m done Moving on out at 4.10

0 · Reply

peepthestamp Jan. 24 at 12:07 AM

$LSTA

0 · Reply

Blu66 Jan. 22 at 4:28 PM

$LSTA Guys watch out...it's about to leave!! Objective $5

1 · Reply

Blu66 Jan. 22 at 4:02 PM

$LSTA buy lisata

0 · Reply

PyraWeb Jan. 22 at 3:19 PM

$LSTA so my theory is IF there is a significant short here, it has to be covered before sale, and I’d expect a pop if there’s a short because this stock is sooo thinly traded. If it doesn’t pop, I’ll be fairly certain all the downturn this stock has ever seen was caused by the company to pay themselves…my recent postings on 1.96 gap level, and the company recently being paid at that level appeared disappointing. Let’s see. Still getting better volume than normal. We’ll know what kind of guy Mazzo is soon, I think. 🤞

0 · Reply

Blu66 Jan. 22 at 10:52 AM

$LSTA buy opportunity

0 · Reply

Stmkr Jan. 22 at 8:05 AM

$LSTA I think market will soon price in the 1st $1.X CVR (i.e. price will move closer to $5). Stock price still trading at $4.X acquisition price (i.e. the up to $2.X CVRs are free). https://substack.com/@biotechpharmainvestor/note/c-203318413?r=2nece1

0 · Reply

Market Cap	40.84M
Revenue (ttm)	1.00M
Net Income (ttm)	-19.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,999.00%
Debt to Equity Ratio	0.00

Volume	190,100
Avg Vol	167,294
Day's Range	N/A - N/A
Shares Out	8.82M
Stochastic %K	64%
Beta	1.11
Analysts	Sell
Price Target	$9.50